By Adriano Marchese
Eupraxia Pharmaceuticals shares rose in premarket trading Tuesday after the company said it received positive data from its eosinophilic esophagitis treatment trials.
Shares traded nearly 6.3% higher in New York at $4.00.
The Toronto and New York-listed biotechnology company said that all three patients that were part of the Resolve phase 1b/2a trial evaluating EP-104GI as a treatment reported reduced symptom severity.
Eosinophilic esophagitis, or EoE, is a chronic immune system disease where a type of white blood cell, called an eosinophil, builds up in the lining of the esophagus and causes averse reactions to certain foods or allergens.
The trial also showed that there was improvement in tissue health among the patients, the largest improvement observed in any of the cohorts to date.
Eupraxia said that these effects are comparable to, or better than, what has been demonstrated by currently approved treatments for EoE.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
February 25, 2025 09:30 ET (14:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。